Ad Header



The Pulse of the Pharmaceutical Industry

EU approves Roche’s Cotellic in combo therapy against skin cancer

Written by: | | Dated: Wednesday, November 25th, 2015


Roche is counting on Cotellic to help it revive flagging sales of five-year-old Zelboraf, which dropped 25 percent during the first nine months of 2015. It has been under intense pressure from rivals’ drugs as the standard of care moves to combination therapy.

The Food and Drug Administration approved the Cotellic-Zelboraf combination in the United States earlier this month, with approval from Switzerland in August.


(Reporting by John Miller)

Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom